These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 26690023)

  • 1. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Muus P; Szer J; Hill A; Höchsmann B; Kulasekararaj A; Risitano AM; Van Den Neste E; Liljeholm M; Ebrahim KS; Bedrosian CL; Gao X; Ames D; Socié G
    Am J Hematol; 2016 Mar; 91(3):E16-7. PubMed ID: 26690023
    [No Abstract]   [Full Text] [Related]  

  • 2. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
    Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
    Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
    Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
    N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
    Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
    Front Immunol; 2019; 10():1157. PubMed ID: 31258525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
    Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
    Keating GM; Lyseng-Williamson KA; McKeage K
    BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
    Lee SE; Lee JW
    Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
    [No Abstract]   [Full Text] [Related]  

  • 9. Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria.
    Waheed A; Kuter DJ
    Am J Hematol; 2021 Jul; 96(7):E235-E237. PubMed ID: 33844861
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
    Röth A; He G; Tong H; Lin Z; Wang X; Chai-Adisaksopha C; Lee JH; Brodsky A; Hantaweepant C; Dumagay TE; Demichelis-Gómez R; Rojnuckarin P; Sun J; Höglund M; Jang JH; Gaya A; Silva F; Obara N; Kelly RJ; Beveridge L; Buatois S; Chebon S; Gentile B; Lundberg P; Sreckovic S; Nishimura JI; Risitano A; Han B
    Am J Hematol; 2024 Sep; 99(9):1768-1777. PubMed ID: 38884175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.
    Guasch A
    Am J Hematol; 2010 Aug; 85(8):551-2. PubMed ID: 20658585
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
    Scheinberg P; Clé DV; Kim JS; Nur E; Yenerel MN; Barcellini W; Bonito D; Giai V; Hus M; Lee Y; Lekue CB; Panse J; Ueda Y; Buatois S; Gentile B; Kiialainen A; Patel H; Sreckovic S; Uguen M; Edwards J; Nagy Z; Kulasekararaj AG
    Am J Hematol; 2024 Sep; 99(9):1757-1767. PubMed ID: 38924124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.
    Pike A; Muus P; Munir T; Mitchell L; Arnold L; Riley K; Houghton N; Forrest B; Gachev J; Hillmen P; Griffin M
    Br J Haematol; 2020 Oct; 191(1):e1-e4. PubMed ID: 32945525
    [No Abstract]   [Full Text] [Related]  

  • 14. No Good Deed Goes Unpunished: Eculizumab and Invasive Neisserial Infections.
    McQuillen DP; Ram S
    Clin Infect Dis; 2019 Aug; 69(4):601-603. PubMed ID: 30418552
    [No Abstract]   [Full Text] [Related]  

  • 15. Neisseria elongata infection associated with complement inhibition during treatment of paroxysmal nocturnal haemoglobinuria.
    Benz R; Krause M; Majer S; Taverna C; Herzog K
    Br J Haematol; 2018 Aug; 182(3):318. PubMed ID: 29676447
    [No Abstract]   [Full Text] [Related]  

  • 16. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).
    Schols S; Nunn MA; Mackie I; Weston-Davies W; Nishimura JI; Kanakura Y; Blijlevens N; Muus P; Langemeijer S
    Br J Haematol; 2020 Jan; 188(2):334-337. PubMed ID: 31840801
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
    Peffault de Latour R; Fremeaux-Bacchi V; Porcher R; Xhaard A; Rosain J; Castaneda DC; Vieira-Martins P; Roncelin S; Rodriguez-Otero P; Plessier A; Sicre de Fontbrune F; Abbes S; Robin M; Socié G
    Blood; 2015 Jan; 125(5):775-83. PubMed ID: 25477495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Wong EK; Kavanagh D
    Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria.
    Chonat S; Kulagin A; Maschan A; Bartels M; Buechner J; Punzalan R; Richards M; Ogawa M; Hicks E; Yu J; Baruchel A; Kulasekararaj AG
    Blood Adv; 2024 Jun; 8(11):2813-2824. PubMed ID: 38551806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.